Vaccination News

With roughly 7% of adults in the United States reporting that they have had long COVID, primary care providers can play an important role in its prevention and management, according to experts.

Researchers developed a low-cost rapid test to detect an invasive species of mosquito that has adapted to live near humans in urban environments, which they hope can be used in areas far from medical labs.

Throughout the course of human history, one infectious disease (Figure 1) may account for more deaths than any other, perhaps all others combined.

The risk for developing long COVID declined over the course of the pandemic but has remained significant, researchers reported.

Ivory Coast administered the first doses of the world’s second malaria vaccine this week, according to the vaccine’s manufacturers, marking the latest development in a decades-long effort to control the deadly mosquito-borne disease.

Data from more than 3 million participants in the National COVID Cohort Collaborative revealed that SARS-CoV-2 reinfections have similar severity to initial infections.

The severity of a SARS-CoV-2 reinfection is likely to be similar to the severity of a patient’s initial infection, researchers found.

A first-in-human trial of a nasal COVID-19 vaccine candidate began enrolling adults aged 18 to 64 years who have received at least three prior doses of a COVID-19 messenger RNA vaccine, according to the NIH.

The monoclonal antibody nirsevimab reduced the risk that infants would be hospitalized for respiratory syncytial virus-associated bronchiolitis, according to a study published Wednesday in The New England Journal of Medicine.

The FDA’s recent authorization of a rapid, point-of-care test to diagnose current hepatitis C virus infection is a major victory, but it would be malpractice to initiate same-day HCV treatment if a patient’s hepatitis B virus status is unknown.